Skip to main content
. 2021 Aug 26;12:718621. doi: 10.3389/fimmu.2021.718621

Figure 5.

Figure 5

Improving ACT Therapy with PI3K-δ and PI3K-γ Inhibition. Five distinct timepoints during ACT manufacturing are identified wherein intervention with PI3K-δ/-γ inhibitors may improve manufactured product quality and clinical outcomes.